Jeffery L. Kutok
No más puestos en curso
Perfil
Jeffery L.
Kutok held several positions throughout his career.
He was an Associate Professor-Pathology at The Brigham & Women's Hospital, Inc. and Harvard Medical School from 2002 to 2010.
He then became the Chief Scientific Officer & Senior Vice President at Infinity Pharmaceuticals, Inc. from 2010 to 2020.
After that, he was the Chief Scientific Officer & Executive VP at Epizyme, Inc. from 2020 to 2022.
Kutok received his undergraduate, graduate, and doctorate degrees from Stony Brook University.
Antiguos cargos conocidos de Jeffery L. Kutok.
Empresas | Cargo | Fin |
---|---|---|
EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 01/09/2022 |
INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/03/2020 |
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/12/2010 |
Harvard Medical School | Corporate Officer/Principal | 01/12/2010 |
Formación de Jeffery L. Kutok.
Stony Brook University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffery L. Kutok